RPTX Key Statistics, Chart & Performance
The current stock price of RPTX is 2.17 USD. In the past month the price increased by 25.58%. In the past year, price increased by 22.03%.
RPTX Latest News, Press Relases and Analysis
RPTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.56 | 393.49B | ||
| AMGN | AMGEN INC | 14.44 | 170.04B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.45B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.19 | 110.94B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.56 | 73.62B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 809.75 | 54.56B | ||
| INSM | INSMED INC | N/A | 41.83B | ||
| NTRA | NATERA INC | N/A | 32.84B | ||
| BIIB | BIOGEN INC | 10.21 | 25.07B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.19 | 20.67B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.24B | ||
| INCY | INCYTE CORP | 15.04 | 18.95B |
Related stock screener links
About RPTX
Company Profile
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 129 full-time employees. The company went IPO on 2020-06-19. The firm utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
Company Info
REPARE THERAPEUTICS INC
7210 Frederick-Banting, Suite 100
ST-LAURENT QUEBEC H4S 2A1 CA
CEO: Lloyd M. Segal
Employees: 129
Phone: 18574127018
REPARE THERAPEUTICS INC / RPTX FAQ
What does REPARE THERAPEUTICS INC do?
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company is headquartered in St-Laurent, Quebec and currently employs 129 full-time employees. The company went IPO on 2020-06-19. The firm utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its pipeline includes RP-3467, a Phase 1 Polo ATPase inhibitor; RP-1664, a Phase 1 PLK4 inhibitor, and lunresertib, a PKMYT1 inhibitor.
What is the current price of RPTX stock?
The current stock price of RPTX is 2.17 USD. The price increased by 0.46% in the last trading session.
Does RPTX stock pay dividends?
RPTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of RPTX stock?
RPTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about REPARE THERAPEUTICS INC (RPTX) stock?
9 analysts have analysed RPTX and the average price target is 3.06 USD. This implies a price increase of 41.01% is expected in the next year compared to the current price of 2.17.
Can you provide the growth outlook for REPARE THERAPEUTICS INC?
The Revenue of REPARE THERAPEUTICS INC (RPTX) is expected to decline by -89.18% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the Short Interest ratio of REPARE THERAPEUTICS INC (RPTX) stock?
The outstanding short interest for REPARE THERAPEUTICS INC (RPTX) is 1.37% of its float.
RPTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RPTX. When comparing the yearly performance of all stocks, RPTX is one of the better performing stocks in the market, outperforming 85.9% of all stocks.
RPTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RPTX. While RPTX has a great health rating, there are worries on its profitability.
RPTX Financial Highlights
Over the last trailing twelve months RPTX reported a non-GAAP Earnings per Share(EPS) of -1.7. The EPS increased by 15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.96% | ||
| ROE | -62.71% | ||
| Debt/Equity | 0 |
RPTX Forecast & Estimates
9 analysts have analysed RPTX and the average price target is 3.06 USD. This implies a price increase of 41.01% is expected in the next year compared to the current price of 2.17.
For the next year, analysts expect an EPS growth of 12.31% and a revenue growth -89.18% for RPTX